Ryan advises clients on intellectual property issues in connection with transactions, including mergers and acquisitions, in- and out-licensing relationships, and venture financings. He evaluates the intellectual property portfolios of target companies, as well as potentially blocking third-party intellectual property.
Ryan works with clients in the biotechnology and biopharmaceutical industries on a wide range of intellectual property issues, including patent portfolio strategy, patent opinions, and freedom-to-operate analysis. Prior to joining the Intellectual Property Transactions group, Ryan prosecuted life sciences patent applications for over eleven years.
Prior to joining the firm, Ryan completed a Ph.D. in genetics from Harvard University, where his graduate work focused on zebrafish genetic cancer models and chemical genetic approaches in the laboratory of Professor Leonard Zon.
Experience
- Advised Partners Group, one of the largest firms in the global private markets industry, on its acquisition – on behalf of its clients – of a majority stake in FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO), from GHO Capital Partners.
- Represented the underwriters in Biohaven Ltd.'s $264.5 million follow-on offering. Biohaven intends to use the proceeds from the offering to fund general corporate purposes.
- Advised a pharmaceuticals and biotechnology company, in the sale to an international pharmaceutical company, specialized in manufacturing and ethical brands for European and ex-US rights to drug treating relapsing forms of multiple sclerosis.
- Represented Blackstone Life Sciences in numerous transactions, including:
- its collaboration with Moderna, Inc. through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza (flu) program;
- Its royalty financing collaboration agreement with a clinical-stage oncology company developing novel site-specific antibody drug conjugates; and
- its combination with gene editing drugmaker Intellia Therapeutics, Inc. and German cell manufacturer Cellex Cell Professionals GmbH to create a new CAR T-cell company to develop cell therapies for cancer and autoimmune diseases.
- Represented a biotechnology manufacturing company in an exclusive option to acquire a spatial proteomic company.
- Represented Intrinsic Medicine, Inc., a therapeutics company leveraging human milk biology to transform Gut-Brain Axis and inflammatory disorders, in a de-SPAC definitive business combination agreement with Phoenix Biotech Acquisition Corp, a special purpose acquisition company.
- Advised IDRx, clinical stage precision cancer biopharmaceutical company, in licensing transactions with Germany-based Merck KGaA and Blueprint Medicines, including a $122 Million Series A Financing, to secure rights to IDRX-42 and IDRX-73- two small molecule tyrosine kinase inhibitors which are designed to inhibit the key genetic drivers and drug-resistant mutations of non-PDGFR-driven gastrointestinal stromal tumor (GIST), a sarcoma of the GI tract.
- Represented ConvaTec Group, a global medical solutions company, in its acquisition of medical device company, Triad Life Sciences, valued up to $425 million.
- Represented Bain Capital Life Sciences LP in a $55 million Series D financing and investment round for Germany biopharmaceutical company InflaRx comprised of a $30 million capital increase and a $25 million secondary share purchase.
- Represented a biotechnology company drafting and prosecuting a broad patent portfolio in the U.S. and around the world.
- Represented a venture capital firm in connection with an investment in a biotechnology company.
- Represented a biopharmaceutical company in a patent interference resulting in a victory for the client.